COMPANY PROFILE

Foldrx Pharmaceuticals

FoldRx Pharmaceuticals is focused on discovering and developing disease-modifying drug therapies for protein misfolding diseases

Cambridge, United StatesFounded 2003Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2010

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Foldrx Pharmaceuticals

Foldrx is a biotechnology company focused on developing treatments for protein misfolding disorders, a class of diseases where proteins do not fold into their correct shapes, leading to various health issues. The company operates in the healthcare and pharmaceutical market, primarily serving patients and healthcare providers. Foldrx's business model revolves around research and development (R&D) of novel therapeutics, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, either directly or through partnerships and licensing agreements with larger pharmaceutical companies.

Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2003
Headquarters: Cambridge, United States
Employees: 2
Open positions: None listed
Dealroom signal: 56.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Genetics and genomics, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Foldrx Pharmaceuticals.

See all news

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Sep 2010	$0	—	Pfizer	—
EARLY VCOther financing	Jun 2010	$29M	$116M	Morgenthaler Ventures · Novartis Venture Fund · Novo Ventures · HealthCare Ventures	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Foldrx Pharmaceuticals website traffic

Latest recorded traffic for Foldrx Pharmaceuticals is 760 monthly website visits, up 484.6% over the last three months. Foldrx Pharmaceuticals's team declined 50% over the past year.

Latest monthly visits760 3-month web change+484.6% 1-year team growth-50%

Monthly website visitsApr 2016–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ABAdverum BiotechnologiesClinical stage gene therapy targeting unmet needs in ocular and rare diseases with durable therapeutic protein expression	Redwood City, United States	Closed	141	$188M	$159M
IMImmusoftImmusoft, a biotechnology company, commercializes technologies that program the human immune system by modifying the DNA in related cells	Seattle, United States	Operational
TBTranslate BioDeveloping mRNA medicines to restore protein function	Cambridge, United States	Acquired
SBScout BioScout Bio is a Health care company	Philadelphia, United States	Acquired
SYSynthorxBiotechnology company using synthetic biology to synthesize solutions	San Diego, United States	Acquired
PDParadigm DiagnosticsPrivate molecular information corporation established to bring cutting-edge diagnostics to cancer patients and industry	Phoenix, United States	Acquired
STStoke TherapeuticsStoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases	Bedford, United States	Operational
DIDIADEMImproves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome	London, United Kingdom	Operational